Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
- Author(s)
- Cragg, MS; Harris, C; Strasser, A; Scott, CL;
- Details
- Publication Year 2009-05,Volume 9,Issue #5,Page 321-326
- Journal Title
- NATURE REVIEWS CANCER
- Publication Type
- Journal Article
- Abstract
- Therapeutic targeting Of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, Cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, Such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.
- Publisher
- NATURE PUBLISHING GROUP
- Keywords
- CELL LUNG-CANCER; BCL-2 FAMILY PROTEINS; SMALL-MOLECULE INHIBITOR; EGFR MUTATIONS; IN-VIVO; ANTAGONIST ABT-737; MULTIPLE-MYELOMA; ABL KINASE; APOPTOSIS; RESISTANCE
- Publisher's Version
- https://doi.org/10.1038/nrc2615
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2009-05-01 12:00:00